DE602004010680T2 - Substituierte imidazopyrimidine zur prävention und behandlung von krebs - Google Patents

Substituierte imidazopyrimidine zur prävention und behandlung von krebs Download PDF

Info

Publication number
DE602004010680T2
DE602004010680T2 DE602004010680T DE602004010680T DE602004010680T2 DE 602004010680 T2 DE602004010680 T2 DE 602004010680T2 DE 602004010680 T DE602004010680 T DE 602004010680T DE 602004010680 T DE602004010680 T DE 602004010680T DE 602004010680 T2 DE602004010680 T2 DE 602004010680T2
Authority
DE
Germany
Prior art keywords
pyrimidine
imidazo
nmr
methylsulfanylphenyl
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004010680T
Other languages
German (de)
English (en)
Other versions
DE602004010680D1 (de
Inventor
Juan Lorenzo Catena Ruiz
Carles Farrerons Gallemi
Anna Fernandez Serrat
Carmen Serra Comas
Dolors Balsa Lopez
Carmen Lagunas Arnal
Carolina Salcedo Roca
Andres Fernandez Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
L V A T LAB SA
Laboratorios Salvat SA
Original Assignee
L V A T LAB SA
Laboratorios Salvat SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L V A T LAB SA, Laboratorios Salvat SA filed Critical L V A T LAB SA
Publication of DE602004010680D1 publication Critical patent/DE602004010680D1/de
Application granted granted Critical
Publication of DE602004010680T2 publication Critical patent/DE602004010680T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004010680T 2003-07-30 2004-07-29 Substituierte imidazopyrimidine zur prävention und behandlung von krebs Expired - Fee Related DE602004010680T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200301906 2003-07-30
ES200301906 2003-07-30
PCT/EP2004/008476 WO2005014598A1 (en) 2003-07-30 2004-07-29 Substituted imidazopyrimidines for the prevention and treatment of cancer

Publications (2)

Publication Number Publication Date
DE602004010680D1 DE602004010680D1 (de) 2008-01-24
DE602004010680T2 true DE602004010680T2 (de) 2009-01-02

Family

ID=34130555

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004010680T Expired - Fee Related DE602004010680T2 (de) 2003-07-30 2004-07-29 Substituierte imidazopyrimidine zur prävention und behandlung von krebs

Country Status (14)

Country Link
US (1) US20060189631A1 (https=)
EP (1) EP1660500B1 (https=)
JP (1) JP2007500160A (https=)
KR (1) KR20060034303A (https=)
CN (1) CN1860121A (https=)
AT (1) ATE380816T1 (https=)
AU (1) AU2004263297A1 (https=)
BR (1) BRPI0412636A (https=)
CA (1) CA2534292A1 (https=)
DE (1) DE602004010680T2 (https=)
EA (1) EA009038B1 (https=)
ES (1) ES2298798T3 (https=)
WO (1) WO2005014598A1 (https=)
ZA (1) ZA200601706B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096764A2 (en) * 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
EP2057164A1 (en) 2006-08-07 2009-05-13 Incyte Corporation Triazolotriazines as kinase inhibitors
RS54510B1 (sr) 2006-11-22 2016-06-30 Incyte Holdings Corporation Imidazotriazini i imidazopirimidini kao inhibitori kinaze
EP2062893A1 (en) * 2007-10-18 2009-05-27 Bayer Schering Pharma AG Fused imidazoles for cancer treatment
WO2009021990A1 (en) * 2007-08-14 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
TWI472529B (zh) 2008-05-21 2015-02-11 Incyte Corp ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
WO2011047320A2 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
MX2012008898A (es) 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
CN102796103A (zh) * 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
BR112016014004B1 (pt) 2013-12-19 2022-11-01 Novartis Ag Compostos para tratamento de doenças parasíticas, seus usos, e composições farmacêuticas
CA2979342A1 (en) 2015-03-11 2016-09-15 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
WO2017193016A1 (en) 2016-05-06 2017-11-09 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455924A (en) * 1967-02-08 1969-07-15 Upjohn Co Dianisylimidazoles
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
ES2140354B1 (es) * 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.

Also Published As

Publication number Publication date
EP1660500A1 (en) 2006-05-31
ES2298798T3 (es) 2008-05-16
EA200600330A1 (ru) 2006-08-25
ATE380816T1 (de) 2007-12-15
WO2005014598A1 (en) 2005-02-17
DE602004010680D1 (de) 2008-01-24
BRPI0412636A (pt) 2006-09-26
KR20060034303A (ko) 2006-04-21
EA009038B1 (ru) 2007-10-26
AU2004263297A1 (en) 2005-02-17
JP2007500160A (ja) 2007-01-11
US20060189631A1 (en) 2006-08-24
ZA200601706B (en) 2007-09-26
EP1660500B1 (en) 2007-12-12
CN1860121A (zh) 2006-11-08
CA2534292A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DE602004010680T2 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
EP0888353B1 (de) N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
DE60225563T2 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
DE69816651T2 (de) 2,3-diaryl-pyrazolo[1,5-b]pyridazin derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
DE602005003362T2 (de) Pyrazolopyrimidine
EP3019493B1 (de) Modifizierte bet-proteininhibitorische dihydrochinoxalinone und dihydropyridopyrazinone
WO2007025540A2 (de) Substituierte imidazo[1,2b]pyridazine als kinase-inhibitoren, deren herstellung und verwendung als arzneimittel
WO2001023386A2 (de) Benzodiazepin-derivate, deren herstellung und anwendung
CN104530052A (zh) 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
WO2014128111A1 (de) 4-substituierte pyrrolo- und pyrazolo-diazepine
WO2009152087A1 (en) Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
WO1997032879A1 (de) 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE
WO2009143018A2 (en) Compounds and methods for kinase modulation, and indications therefor
EP1521756A1 (de) Heterocyclisch substituierte imidazotriazine
DE69427023T2 (de) Tricyclische benzazepin-und benzothiazepin derivate
WO1999043678A1 (en) Remedies/preventives for parkinson's disease
DE3888897T2 (de) Imidazo[1,2-b]pyridazinderivate.
WO2008015265A1 (de) Anthracen-derivate und deren verwendung zur behandlung gutartiger und bösartiger tumorerkrankungen
MX2007007218A (es) Compuestos de pirazolo-heteroarilo utiles para tratar enfermedades mediadas por factor de necrosis tumoral alfa (tnf-alfa) e interleucina-1 (il-1).
DE69521209T2 (de) Triazolopyridazine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als arzneimittel
WO2015121230A1 (de) 9-substituierte 2,3-benzodiazepine
N’ta Ambeu et al. Microwave synthesis of new 3-(3-aminopropyl)-5-arylidene-2-thioxo-1, 3-thiazolidine-4-ones as potential Ser/Thr protein kinase inhibitors
WO2015193228A1 (de) Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
Keshari et al. Novel Mannich-bases as potential anticonvulsants: syntheses, characterization and biological evaluation
WO2015121227A1 (de) 6,9-disubstituierte 1 -phenyl-3h-2,3-benzodiazepine und ihre verwendung als bromodomänen- inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee